Srinagar Magazine

Cerebral Adrenoleukodystrophy Epidemiology Forecast to 2030 by DelveInsight

 Breaking News
  • No posts were found

Cerebral Adrenoleukodystrophy Epidemiology Forecast to 2030 by DelveInsight

January 25
14:38 2021
Cerebral Adrenoleukodystrophy Epidemiology Forecast to 2030 by DelveInsight

DelveInsight has launched a new report on Cerebral Adrenoleukodystrophy Epidemiology

Cerebral Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.

Get a free sample copy- https://www.delveinsight.com/report-store/cerebral-adrenoleukodystrophy-cald-epidemiology-forecast

An all-inclusive account of both the current and Cerebral Adrenoleukodystrophy emerging therapies for Cerebral Adrenoleukodystrophy, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

Cerebral Adrenoleukodystrophy Epidemiology

Cerebral Adrenoleukodystrophy is a genetic disorder that occurs primarily in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. In this disorder, the fatty covering (myelin) that insulates nerves in the brain and spinal cord is prone to deterioration (demyelination), which reduces the ability of the nerves to relay information to the brain.

Key facts of the Cerebral Adrenoleukodystrophy report

  • In 2017, the total prevalent population of ALD in the 7MM was 55,242.
  • ALD in the 7MM was 55,242. As per “The Stop ALD Foundation”, Adrenoleukodystrophy, or ALD, is a deadly genetic disease that affects 1 in 18,000 people. Cerebral Adrenoleukodystrophy (CALD) is the most common form of ALD, representing approximately 90% of all ALD cases.
  • In 2017, the prevalent population of ALD in the US was 19,371.
  • As per the National Institute of Health (NIH), CALD manifests in 70% of male and 2% of female cases of ALD, with estimated birth incidence (male and female) 1 per 20,000.

Cerebral Adrenoleukodystrophy Epidemiology Segmentation

  • Total Diagnosed Prevalent Population of Cerebral Adrenoleukodystrophy in the 7MM [2017–2030]
  • Gender-specific Diagnosed Prevalent Population of Cerebral Adrenoleukodystrophy in the 7MM [2017–2030]
  • Total Diagnosed Prevalent Population of Cerebral Adrenoleukodystrophy in the 7MM [2017–2030]
  • Age-specific Diagnosed Prevalence of Cerebral Adrenoleukodystrophy in Males in the 7MM [2017–2030]

Cerebral Adrenoleukodystrophy Symptoms

The symptoms of CALD include learning disabilities, behavioral problems, bowel incontinence, adrenal insufficiency, loss of vision, deafness, seizures, loss of brain and muscle tissue.

 

Cerebral Adrenoleukodystrophy Treatment

General supportive care and symptomatic treatment for patient and family, provided by pediatrician or neurologist, with appropriate specialist consultation, nursing, schools, rehabilitation, and social agencies, are the cornerstones for the care and treatment of patients with CALD. Currently, there are no approved therapies for the treatment of CALD, and it is primarily managed by hormone replacement therapy, dietary therapy with Lorenzo’s oil, and Hematopoietic stem cell transplantation.

 

Get a free sample copy – https://www.delveinsight.com/report-store/cerebral-adrenoleukodystrophy-cald-epidemiology-forecast

 

Table of content

1. Key Insights 

2. Executive Summary of Cerebral Adrenoleukodystrophy (CALD)

3. Cerebral Adrenoleukodystrophy (CALD): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Reasons to buy

The Cerebral Adrenoleukodystrophy (CALD) Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Cerebral Adrenoleukodystrophy (CALD) market
  • Quantify patient populations in the global Cerebral Adrenoleukodystrophy (CALD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cerebral Adrenoleukodystrophy (CALD) therapeutics in each of the markets covered
  • Understand the magnitude of Cerebral Adrenoleukodystrophy (CALD) population by its epidemiology
  • The Cerebral Adrenoleukodystrophy (CALD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/